Euthyrox

Levothyroxine Na

Benign euthyroid goitre. Prophylaxis of relapse after surgery for euthyroid goitre. Substitution therapy in hypothyroidism. Suppression therapy in thyroid cancer. Concomitant supplementation during antithyroid drug treatment of hyperthyroidism. 100 mcg: Diagnostic thyroid suppression testing.

Benign euthyroid goitre & prophylaxis of relapse after surgery for euthyroid goitre 75-200 mcg daily. Substitution therapy in hypothyroidism Adult Initially: 25-50 mcg daily. Maintenance: 100-200 mcg daily. Childn Initially: 12.5-50 mcg daily. Maintenance: 100-150 mcg/m² daily. Concomitant supplementation during antithyroid drug treatment of hyperthyroidism 50-100 mcg daily. Suppression therapy in thyroid cancer 150-300 mcg daily. Diagnostic use for thyroid suppression testing, wk 2 & wk 1 prior test 200 mcg daily. Duration of treatment: Benign euthyroid goitre 6 mth up to 2 yr.

Should be taken on an empty stomach: Take 30 min before breakfast. Daily doses can be given in single administration. For infants, disintegrate in some water & give resultant susp w/ some more liqd. Susp must be freshly prepared.

Hypersensitivity. Untreated adrenal & pituitary insufficiency, untreated thyrotoxicosis. Not to be initiated in acute MI, myocarditis & pancarditis. Combination therapy w/ antithyroid agent during pregnancy.

Not to be given in hyperthyreotic states & for wt reduction. Secondary hypothyroidism; CHD; severe or long-existing hypothyroidism. Coronary failure, angina pectoris, arteriosclerosis, HTN, pituitary, adrenal & cardiac insufficiency, tachycardiac arrhythmias; thyroid autonomy. Monitor patients at risk of psychotic disorders. Regularly check & monitor thyroid function. Postmenopausal women w/ increased risk of osteoporosis. Diabetics & patients under anticoagulant therapy. Interference w/ biotin/streptavidin interaction-based thyroid immunoassays. Co-administration w/ orlistat. Pregnancy & lactation. Monitor haemodynamic parameters during therapy in very low birth wt preterm neonates. Elderly.

Cardiac arrhythmias, tachycardia, palpitations, anginal conditions, cephalalgia, muscular weakness & cramps, flushing, fever, vomiting, menstrual disorders, pseudotumor cerebri, tremor, restlessness, insomnia, hyperhidrosis, wt loss, diarrhoea. Hypersensitivity.

Reduced antidiabetic effects. Intensified coumarin derivatives effects. Effects influenced by PIs eg, ritonavir, indinavir, lopinavir; phenytoin. Inhibited absorption w/ ion exchange resins eg, cholestyramine, colestipol. Decreased effect w/ Al-, Fe- & Ca-containing drugs. Elevated FT₄ fraction w/ salicylates, dicumarol, high-dose furosemide (250 mg), clofibrate. Decreased absorption w/ PPIs, sevelamer. Hypothyroidism &/or reduced control of hypothyroidism w/ orlistat. Decreased efficacy by tyrosine kinase inhibitors eg, imatinib, sunitinib; sertraline, chloroquine/proguanil. Inhibited peripheral T₄-T₃ conversion w/ propylthiouracil, glucocorticoids, β-sympatholytics, amiodarone, iodine-containing contrast media. Increased serum TSH level w/ sertraline, chloroquine/proguanil. Increased hepatic clearance by barbiturates, carbamazepine or St. John's wort-containing products (Hypericum perforatum L.). Increased need of levothyroxine in women using oestrogen-containing contraceptives or post-menopausal women under HRT. Decreased intestinal absorption w/ soy-containing compd. Falsely decreased/increased thyroid immunoassay test results w/ biotin.

Thyroid Hormones

H03AA01 - levothyroxine sodium ; Belongs to the class of thyroid hormones.

C